|
|
Shinichiro Ryu, Shohta Kodama, Kazuko Ryu, David A. Schoenfeld, Denise L. Faustman
J Clin Invest. 2001;
108(1):63
doi:10.1172/JCI12335
Abstract |
Full text
| PDF

I
n NOD (nonobese diabetic) mice, a model of autoimmune diabetes, various immunomodulatory interventions prevent progression to diabetes. However, after hyperglycemia is established, such interventions rarely alter the course of disease or allow sustained engraftment of islet transplants. A proteasome defect in lymphoid cells of NOD mice impairs the presentation of self antigens and increases the susceptibility of these cells to TNF-α–induced apoptosis. Here, we examine the hypothesis that induction of TNF-α expression combined with reeducation of newly emerging T cells with self antigens can interrupt autoimmunity. Hyperglycemic NOD mice were treated with CFA to induce TNF-α expression and were exposed to functional complexes of MHC class I molecules and antigenic peptides either by repeated injection of MHC class I matched splenocytes or by transplantation of islets from nonautoimmune donors. Hyperglycemia was controlled in animals injected with splenocytes by administration of insulin or, more effectively, by implantation of encapsulated islets. These interventions reversed the established β cell–directed autoimmunity and restored endogenous pancreatic islet function to such an extent that normoglycemia was maintained in up to 75% of animals after discontinuation of treatment and removal of islet transplants. A therapy aimed at the selective elimination of autoreactive cells and the reeducation of T cells, when combined with control of glycemia, is thus able to effect an apparent cure of established type 1 diabetes in the NOD mouse.J. Clin. Invest. 108:63–72 (2001). DOI:10.1172/JCI200112335.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(11)
| Title and authors |
Publication |
Year |
Immunotherapy on Trial for New-Onset Type 1 Diabetes
Denise L. Faustman
|
N Engl J Med
|
2008 |
Development and function of the mammalian spleen
Andrea Brendolan, Maria Manuela Rosado, Rita Carsetti, Licia Selleri, T. Neil Dear
|
Bioessays
|
2007 |
Millionaires' pet projects
Katharine Sanderson
|
news@nature
|
2007 |
Prospective prediction of spontaneous but not recurrent autoimmune diabetes in the non-obese diabetic mouse
J. D. Trudeau, T. Chandler, G. Soukhatcheva, C. B. Verchere, R. Tan
|
Diabetologia
|
2007 |
Reversal of Type 1 Diabetes in Mice
Denise L. Faustman
|
N Engl J Med
|
2007 |
Reversal of Type 1 diabetes mellitus without exogenous cells
Dario O Fauza
|
Regenerative Medicine
|
2006 |
Stem-cell therapy for hepatobiliary pancreatic disease
Takahisa Fujikawa, Seh-Hoon Oh, Tom Shupe, Bryon E. Petersen
|
J Hepatobiliary Pancreat Surg
|
2005 |
Systemic Transforming Growth Factor-??1 Gene Therapy Induces Foxp3+ Regulatory Cells, Restores Self-Tolerance, and Facilitates Regeneration Of Beta Cell Function in Overtly Diabetic Nonobese Diabetic Mice
Xunrong Luo, Hua Yang, Il Soo Kim, Fludd Saint-Hilaire, Dolca A. Thomas, Bishnu P. De, Engin Ozkaynak, Thangamani Muthukumar, Wayne W. Hancock, Ronald G. Crystal, Manikkam Suthanthiran
|
Transplantation
|
2005 |
Opinion: Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes
Bart O. Roep, Mark Atkinson, Matthias von Herrath
|
Nat Rev Immunol
|
2004 |
Routes to regenerating islet cells: stem cells and other biological therapies for type 1 diabetes
Shohta Kodama, Denise L. Faustman
|
Pediatric Diabetes
|
2004 |
|